Wells Fargo & Company MN maintained its position in Curis, Inc. (NASDAQ:CRIS) during the first quarter, according to its most recent disclosure with the SEC. The firm owned 91,055 shares of the biotechnology company’s stock at the end of the first quarter. Wells Fargo & Company MN owned 0.06% of Curis worth $253,000 as of its most recent filing with the SEC.
Other institutional investors have also bought and sold shares of the company. A.R.T. Advisors LLC acquired a new position in Curis during the fourth quarter worth approximately $116,000. Two Sigma Investments LP acquired a new position in Curis during the fourth quarter worth approximately $183,000. Metropolitan Life Insurance Co. NY increased its position in Curis by 7.3% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 82,518 shares of the biotechnology company’s stock worth $254,000 after buying an additional 5,585 shares in the last quarter. Janney Montgomery Scott LLC increased its position in Curis by 11.1% in the first quarter. Janney Montgomery Scott LLC now owns 123,644 shares of the biotechnology company’s stock worth $344,000 after buying an additional 12,344 shares in the last quarter. Finally, Renaissance Technologies LLC increased its position in Curis by 152.0% in the fourth quarter. Renaissance Technologies LLC now owns 361,100 shares of the biotechnology company’s stock worth $1,112,000 after buying an additional 217,800 shares in the last quarter. Institutional investors own 51.63% of the company’s stock.
Shares of Curis, Inc. (CRIS) opened at 2.04 on Friday. Curis, Inc. has a one year low of $1.56 and a one year high of $3.72. The stock has a 50 day moving average of $1.93 and a 200-day moving average of $2.39. The company’s market capitalization is $293.29 million.
Curis (NASDAQ:CRIS) last released its quarterly earnings results on Thursday, May 4th. The biotechnology company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.09) by $0.02. Curis had a negative return on equity of 163.29% and a negative net margin of 841.05%. The firm had revenue of $2.13 million for the quarter, compared to analysts’ expectations of $1.98 million. During the same quarter last year, the firm posted ($0.07) earnings per share. The firm’s revenue for the quarter was up 23.1% compared to the same quarter last year. On average, equities analysts forecast that Curis, Inc. will post ($0.40) earnings per share for the current fiscal year.
WARNING: “Curis, Inc. (CRIS) Stake Maintained by Wells Fargo & Company MN” was first posted by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this report on another domain, it was illegally copied and reposted in violation of U.S. & international copyright & trademark legislation. The correct version of this report can be read at https://stocknewstimes.com/2017/07/21/curis-inc-cris-stake-maintained-by-wells-fargo-company-mn.html.
CRIS has been the topic of a number of research analyst reports. ValuEngine raised shares of Curis from a “sell” rating to a “hold” rating in a report on Thursday, June 22nd. Zacks Investment Research cut shares of Curis from a “hold” rating to a “sell” rating in a report on Wednesday, May 10th. Finally, Cowen and Company reaffirmed a “buy” rating on shares of Curis in a report on Friday, May 5th. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Curis currently has a consensus rating of “Buy” and an average price target of $5.88.
In related news, Director James R. Mcnab sold 76,276 shares of the business’s stock in a transaction dated Friday, May 5th. The shares were sold at an average price of $2.04, for a total transaction of $155,603.04. Following the transaction, the director now directly owns 879,688 shares in the company, valued at $1,794,563.52. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director James R. Mcnab sold 146,694 shares of the business’s stock in a transaction dated Thursday, April 27th. The stock was sold at an average price of $2.61, for a total transaction of $382,871.34. Following the transaction, the director now owns 912,426 shares in the company, valued at $2,381,431.86. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 450,000 shares of company stock worth $1,101,973. 4.07% of the stock is owned by corporate insiders.
About Curis
Curis, Inc is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company’s drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes.
Receive News & Ratings for Curis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
